Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell DiseasePRNewsWire • 01/22/25
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should KnowZacks Investment Research • 01/17/25
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top PicksZacks Investment Research • 01/09/25
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short TermZacks Investment Research • 12/23/24
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionPRNewsWire • 12/09/24
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDSPRNewsWire • 12/02/24
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%Zacks Investment Research • 11/19/24
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/07/24
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/05/24
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business UpdatePRNewsWire • 10/31/24
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)PRNewsWire • 10/24/24
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®GlobeNewsWire • 10/16/24
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic PartnershipsSeeking Alpha • 10/10/24